Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01259323 · ClinicalTrials.gov registry record · Phase 1
Sequential Ascending Dose Study to Assess the Safety and Tolerability of REGN668 (SAR231893) in Patients With Atopic Dermatitis
A Phase 1 study of Dermatitis, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 10
- Study locations
NCT01259323: Completed Phase 1 study of Dermatitis, sponsored by Regeneron Pharmaceuticals.
NCT01259323 is a Phase 1 study of Dermatitis that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 30 participants, below the 174-participant average among 6 other Dermatitis trials with a reported enrollment target (83% lower). The trial reports 10 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01259323, a Phase 1 study of Dermatitis, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 10
- Study locations
Study Summary
The purpose of this study is to assess the Safety and Tolerability of REGN668 (how the body reacts to the drug) compared to placebo (an inert substance) in patients with moderate-to-severe extrinsic Atopic Dermatitis.
Conditions Studied
Interventions
- BIOLOGICAL REGN668
Study Locations (10)
California
- - Los Angeles
- - Riverside
New York
- - New York
- - Rochester
Florida
- - Miami
Illinois
- - Chicago
Michigan
- - Troy
Oregon
- - Portland
Pennsylvania
- - Philadelphia
Texas
- - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2010-12 |
| Est. Completion | 2012-07 |
| Phase | Phase 1 |
What the finished NCT01259323 record still lists
NCT01259323 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 174-participant average among 6 other Dermatitis trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Dermatitis appearing as the primary indexed condition, and to 1 intervention - of which REGN668 is the first listed.
NCT01259323 lists 10 locations in 8 states (California, New York, Florida).
Frequently Asked Questions
What is clinical trial NCT01259323 about?
NCT01259323 is a clinical study titled "Sequential Ascending Dose Study to Assess the Safety and Tolerability of REGN668 (SAR231893) in Patients With Atopic Dermatitis". The purpose of this study is to assess the Safety and Tolerability of REGN668 (how the body reacts to the drug) compared to placebo (an inert substance) in patients with moderate-to-severe extrinsic Atopic Dermatitis.
What is the current status of trial NCT01259323?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2010-12. Estimated completion is 2012-07.
What conditions does trial NCT01259323 study?
This clinical trial studies the following conditions: Dermatitis.
What interventions are being tested in trial NCT01259323?
The interventions under investigation include: REGN668 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01259323?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01259323 being conducted?
This trial has 10 study locations across California, Florida, Illinois, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effects of Treatments on Atopic Dermatitis
RECRUITING · Phase 2
-
ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Infant Fecal Insult Study
COMPLETED · NA
-
Evaluating for Contact Allergies in Patients With Chronic Urticaria
COMPLETED
-
Assessment of Digital Imaging as a Tool for Diagnosing Psoriasis, Hand Rashes and Unusual Moles
COMPLETED
-
A Study to Evaluate Risankizumab in Adults and Adolescents With Moderate to Severe Atopic Dermatitis
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia